Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evobrutinib Effect on COC PK in Healthy Females
NCT07215806Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of evobrutinib in multiple sclerosis (MS), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity and Maximum Observed Plasma Concentration. Started Aug 2022; status: completed.
02
Drugs
evobrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07215806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215806.